Liposomal Doxorubicin Market to hit US$ 2.05 Billion by

Pune, Oct. 27, 2022 (GLOBE NEWSWIRE) — According to a new market research report titled, “Liposomal Doxorubicin Market by Drug Formulation (Lyophilized Powder and Doxorubicin Injection), by Application (Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Others), by Distribution Channel (Hospital, Retail, and Online Pharmacies) – Global Outlook & Forecast Period 2022-2030″ published by Growth Plus Reports, the liposomal doxorubicin market is expected to grow at a CAGR of 5.4% from 2021 to reach US$ 2.05 billion by 2030. Owing to the increasing number of cancer cases globally, technological advancement, and increased awareness.

Get a Sample Copy of the Research Report: https://growthplusreports.com/inquiry/request-sample/liposomal-doxorubicin-market/7903

Market Driver

liposomal doxorubicin is in great demand due to its application in treating cancer, Kaposi sarcoma, and numerous other illnesses. The growth of advanced drug delivery techniques, increased patient awareness, rising disposable incomes, and rising cancer incidence all contribute to the global market growth of liposomal doxorubicin. Sales of liposomal doxorubicin are anticipated to grow after the failure of earlier systemic treatment for ovarian cancer and AIDS-related Kaposi’s sarcoma. The increasing incidence of hepatocellular carcinoma and improving survival rates further boost the market for liposomal doxorubicin. Furthermore, the demand for liposomal doxorubicin is expanding as more people become aware of the numerous cancer therapy choices available. Site-specific drug delivery and controlled drug release within the body are made possible through innovations. Additionally, it is anticipated that the expansion of the market will be accelerated soon by the development of the healthcare infrastructure.

Excerpts from ‘By Application Segmentation’

Based on application, the global liposomal doxorubicin market has been segmented into:

• Bladder Cancer
• Kaposi…